<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777335</url>
  </required_header>
  <id_info>
    <org_study_id>TRIO 016</org_study_id>
    <nct_id>NCT00777335</nct_id>
  </id_info>
  <brief_title>Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the benefit of panobinostat monotherapy given either&#xD;
      orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very low recruitement rate.&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response (OR) Rate (as Determined by the Investigator): the Number of Patients Assigned to a Treatment Arm With a Confirmed Best Response of Complete Response(CR) or Partial Response (PR).</measure>
    <time_frame>At screening, every 2 cycles (i.e. 6 weeks) during the first 6 cycles, every 3 cycles (i.e. 9 weeks) during the subsequent cycles and at the End of Treatment (EOT) visit. After the EOT, the tumor assessments should be performed every 9 weeks.</time_frame>
    <description>The assessment of OR is based on the response of target lesion, of non-target lesion and on presence of new lesions (RECIST Criteria (V1.0)-assessed by CT scan spiral and bone scan)&#xD;
CR:Disappearance of all target lesions&#xD;
PR:&gt;=30% increase in the sum of the longest diameter (SLD),taking as reference the nadir SLD&#xD;
Progressive Disease (PD):&gt;=20% increase in the SLD, taking as reference the nadir SLD, or the appearance of one or more new lesions&#xD;
Stable Disease(SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the nadir SLD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corrected QT Interval Fridericia's Formula (QTcF)</measure>
    <time_frame>Panobinostat intra-venous (i.v.): All cycles pre-dose measurements. For cycles 1 and 2, post-dose measurements as well. / Panobinostat oral: Pre-dose and post-dose measurements for all cycles. Note: each cycle = 3 weeks</time_frame>
    <description>Prolonged QTcF: QTcF &gt;450 msec and increase of baseline on greater than or equal to 60 msec.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Panobinostat i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panobinostat oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat - LBH589</intervention_name>
    <description>Solution for infusion - 25mg/5ml</description>
    <arm_group_label>Panobinostat i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat - LBH589</intervention_name>
    <description>Hard gelatine capsules - 5mg and 20 mg</description>
    <arm_group_label>Panobinostat oral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained prior to any study-related procedures&#xD;
&#xD;
          -  Women ≥ 18 years old&#xD;
&#xD;
          -  Patients with an ECOG performance status of ≤ 2 assessed within 2 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast carcinoma with locally&#xD;
             recurrent or radiological evidence of metastatic disease. Locally recurrent disease&#xD;
             must not be amenable to resection with curative intent.&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             guidelines&#xD;
&#xD;
          -  HER2-positive breast cancer patients by local laboratory testing&#xD;
&#xD;
          -  Prior trastuzumab-containing regimen (in neoadjuvant and/or adjuvant and/or metastatic&#xD;
             settings) regardless of whether trastuzumab was given as monotherapy or in combination&#xD;
             with chemotherapy. Any number of prior trastuzumab regimens is acceptable. Additional&#xD;
             treatment with lapatinib after or before trastuzumab treatment is permitted, but not&#xD;
             mandatory.&#xD;
&#xD;
          -  Radiological evidence of relapse or disease progression while on trastuzumab (or&#xD;
             lapatinib) or within 12 months of the last dose of adjuvant trastuzumab.&#xD;
&#xD;
          -  Complete radiology and tumor assessment within 4 weeks prior to randomization:&#xD;
&#xD;
               -  Chest: Computed Tomography(CT) scan with intravenous contrast if the contrast is&#xD;
                  not medically contraindicated or Magnetic Resonance Imaging(MRI)&#xD;
&#xD;
               -  Abdomen: CT scan with intravenous and oral contrast if the contrast is not&#xD;
                  medically contraindicated or MRI&#xD;
&#xD;
               -  Brain: CT scan or MRI&#xD;
&#xD;
               -  Bone: Whole body Bone Scintigraphy&#xD;
&#xD;
          -  Up to 2 prior cytotoxic chemotherapy regimens, in addition to neo-adjuvant and&#xD;
             adjuvant, for treatment of metastatic or locally recurrent breast cancer (including&#xD;
             those cytotoxic chemotherapy treatments in combination with trastuzumab and/or&#xD;
             lapatinib)&#xD;
&#xD;
          -  Patients must meet the following laboratory criteria within 2 weeks (14 days) prior to&#xD;
             randomization:&#xD;
&#xD;
          -  Hematology&#xD;
&#xD;
          -  Neutrophil count of &gt; 1200/mm3&#xD;
&#xD;
          -  Platelet count of &gt; 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 90 g/L&#xD;
&#xD;
          -  Biochemistry&#xD;
&#xD;
          -  Aspartate aminotransferase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine&#xD;
             aminotransferase/glutamic pyruvic transaminase(ALT/SGPT) ≤ 2.5 x upper limit of normal&#xD;
             (ULN) or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Serum potassium, sodium, magnesium, phosphorus, total calcium (corrected for serum&#xD;
             albumin) or ionized calcium within normal limits for the institution&#xD;
&#xD;
          -  Serum albumin ≥ Lower Limit of Normal(LLN) or 30g/L&#xD;
&#xD;
          -  Clinically euthyroid function (thyroid-stimulating hormone (TSH) and free T4).&#xD;
             (Patients are permitted to receive thyroid hormone supplements to treat underlying&#xD;
             hypothyroidism).&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction(LVEF) assessment (2-D echocardiogram or Multiple&#xD;
             Uptake Gated Acquisition Scan(MUGA) scan) performed within 6 weeks prior to&#xD;
             randomization, showing a LVEF value &gt; 50%&#xD;
&#xD;
          -  Electrocardiogram performed within 1 week prior to randomization (details about&#xD;
             findings on the Electrocardiogram that are not acceptable for participating in the&#xD;
             study are reported in the Exclusion criteria section)&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 7 days prior to randomization and agree to appropriate method of pregnancy&#xD;
             prevention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior Histone Deacetylase(HDAC),Deacetylase(DAC), Heat Shock Protein 90 (HSP90)&#xD;
             inhibitors or valproic acid for the treatment of cancer&#xD;
&#xD;
          -  Patients who will need valproic acid for any medical condition during the study or&#xD;
             within 5 days prior to first panobinostat treatment&#xD;
&#xD;
          -  Patients who have received prior chemotherapy or investigational agent within the last&#xD;
             4 weeks prior to randomization (6 weeks for nitrosoureas and mitomycin; 2 weeks for&#xD;
             capecitabine)&#xD;
&#xD;
          -  Patients who have received prior radiotherapy to ≥ 25% of the bone marrow within the&#xD;
             last 4 weeks prior to randomization; local radiotherapy is allowed however all&#xD;
             recently irradiated lesions should not be included in the measurable disease&#xD;
             assessment&#xD;
&#xD;
          -  Patients who have received prior investigational agents within the last 4 weeks prior&#xD;
             to randomization&#xD;
&#xD;
          -  Patients with unresolved diarrhea ≥CTCAE (National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events) grade 1&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral panobinostat&#xD;
&#xD;
          -  History of cardiac dysfunction including any one of the following:&#xD;
&#xD;
          -  Complete left bundle branch block or necessity for a permanent cardiac pacemaker or&#xD;
             congenital long QT syndrome or history or presence of ventricular tachyarrhythmias or&#xD;
             clinically significant resting bradycardia (&lt;50 beats per minute) or QTcF &gt; 450 msec&#xD;
             on screening electrocardiogram(ECG) or right bundle branch block and left anterior&#xD;
             hemiblock (bifascicular block)&#xD;
&#xD;
          -  Presence of unstable atrial fibrillation (ventricular response rate &gt;100 bpm).&#xD;
             Patients with stable atrial fibrillation are allowed in the study provided they do not&#xD;
             meet the other cardiac exclusion criteria&#xD;
&#xD;
          -  Previous history angina pectoris or acute myocardial infarction(MI) within 6 months of&#xD;
             randomization&#xD;
&#xD;
          -  Congestive heart failure (New York Heart Association functional classification III-IV)&#xD;
&#xD;
          -  Other clinically significant heart disease (e.g. cardiomyopathy, cardiac artery&#xD;
             disease, uncontrolled hypertension, or history of poor compliance with an&#xD;
             antihypertensive regimen)&#xD;
&#xD;
          -  Acute or chronic liver or renal disease&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled&#xD;
             diabetes mellitus, active untreated or uncontrolled infection, chronic obstructive or&#xD;
             chronic restrictive pulmonary disease including dyspnoea at rest from any cause) that&#xD;
             could cause unacceptable safety risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Concomitant use of drugs with a risk of causing torsades de pointes where such&#xD;
             treatments cannot be discontinued or switched to a different medication prior to&#xD;
             starting study drug&#xD;
&#xD;
          -  Brain metastases, unless patient randomized on study at least 90 days from completion&#xD;
             of brain radiotherapy and / or surgery without radiologic or functional evidence of&#xD;
             progressive brain metastases, and off corticosteroids above the dose of 7.5 mg&#xD;
             prednisone or equivalent; No concurrent radiotherapy for brain metastasis is allowed&#xD;
&#xD;
          -  Clinically significant third space fluid accumulation&#xD;
&#xD;
          -  Concurrent bisphosphonates unless if initiated prior to study entry (at least 4 weeks&#xD;
             before study randomization)&#xD;
&#xD;
          -  Pregnant (i.e., positive beta-human chorionic gonadotropin test) or breast feeding&#xD;
&#xD;
          -  Unable to swallow oral medications&#xD;
&#xD;
          -  Not willing to use a double barrier method of non-hormonal birth control.&#xD;
             Contraception must be used during the study and for 90 days after last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Patients with any significant history of non-compliance to medical regimens or with&#xD;
             inability to grant a reliable informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Finn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>January 6, 2012</results_first_submitted>
  <results_first_submitted_qc>March 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2012</results_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 28 sites in 4 countries (USA, Canada, France, Belgium).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Panobinostat Intra-venous (i.v.)</title>
        </group>
        <group group_id="P2">
          <title>Panobinostat Oral</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panobinostat Intra-venous (i.v.)</title>
        </group>
        <group group_id="B2">
          <title>Panobinostat Oral</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="20.8"/>
                    <measurement group_id="B2" value="59.0" spread="11.5"/>
                    <measurement group_id="B3" value="53.5" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status (ECOG PS)</title>
          <description>6-point (0 to 5)ordinal scale to assess how the disease affects the daily living abilities of the patient and determine appropriate treatment and prognosis.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PS 0 (Fully active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 1 (Restricted in physically strenuous activity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 2 (Ambulatory and capable of all selfcare)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 3 (Capable of only limited selfcare)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 4 (Completely disabled)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 5 (Dead)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lines of prior chemotherapy in metastatic setting</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 line of prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 lines of prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 lines of prior chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response (OR) Rate (as Determined by the Investigator): the Number of Patients Assigned to a Treatment Arm With a Confirmed Best Response of Complete Response(CR) or Partial Response (PR).</title>
        <description>The assessment of OR is based on the response of target lesion, of non-target lesion and on presence of new lesions (RECIST Criteria (V1.0)-assessed by CT scan spiral and bone scan)&#xD;
CR:Disappearance of all target lesions&#xD;
PR:&gt;=30% increase in the sum of the longest diameter (SLD),taking as reference the nadir SLD&#xD;
Progressive Disease (PD):&gt;=20% increase in the SLD, taking as reference the nadir SLD, or the appearance of one or more new lesions&#xD;
Stable Disease(SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the nadir SLD</description>
        <time_frame>At screening, every 2 cycles (i.e. 6 weeks) during the first 6 cycles, every 3 cycles (i.e. 9 weeks) during the subsequent cycles and at the End of Treatment (EOT) visit. After the EOT, the tumor assessments should be performed every 9 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat Intra-venous (i.v.)</title>
          </group>
          <group group_id="O2">
            <title>Panobinostat Oral</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Response (OR) Rate (as Determined by the Investigator): the Number of Patients Assigned to a Treatment Arm With a Confirmed Best Response of Complete Response(CR) or Partial Response (PR).</title>
          <description>The assessment of OR is based on the response of target lesion, of non-target lesion and on presence of new lesions (RECIST Criteria (V1.0)-assessed by CT scan spiral and bone scan)&#xD;
CR:Disappearance of all target lesions&#xD;
PR:&gt;=30% increase in the sum of the longest diameter (SLD),taking as reference the nadir SLD&#xD;
Progressive Disease (PD):&gt;=20% increase in the SLD, taking as reference the nadir SLD, or the appearance of one or more new lesions&#xD;
Stable Disease(SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the nadir SLD</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Reponse (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected QT Interval Fridericia's Formula (QTcF)</title>
        <description>Prolonged QTcF: QTcF &gt;450 msec and increase of baseline on greater than or equal to 60 msec.</description>
        <time_frame>Panobinostat intra-venous (i.v.): All cycles pre-dose measurements. For cycles 1 and 2, post-dose measurements as well. / Panobinostat oral: Pre-dose and post-dose measurements for all cycles. Note: each cycle = 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Panobinostat Intra-venous (i.v.)</title>
          </group>
          <group group_id="O2">
            <title>Panobinostat Oral</title>
          </group>
        </group_list>
        <measure>
          <title>Corrected QT Interval Fridericia's Formula (QTcF)</title>
          <description>Prolonged QTcF: QTcF &gt;450 msec and increase of baseline on greater than or equal to 60 msec.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Electrocardiogram QT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram QT prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The period for collection and reporting of adverse events extends from the time the patient signs the informed consent form (even if the event is not considered to be related to the study drug) until 28 days after the last receipt of the study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Panobinostat Intra-venous (i.v.)</title>
        </group>
        <group group_id="E2">
          <title>Panobinostat Oral</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.0</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgueusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The recruitment rate has shown to be very low worldwide. In total, 4 patients only were recruited, instead of the 132 initially targeted. Due to the very small number of subjects randomized in this study, only descriptive analyses have been made.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard Finn</name_or_title>
      <organization>University of California Los Angeles (UCLA) / Cancer International Research Group (CIRG) (Translational Research in Oncology TRIO) Inc.</organization>
      <phone>+ 1 310 586 2091</phone>
      <email>RFinn@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

